Neuroleptic discontinuation syndromes
Abstract
The existence of discontinuation syndromes following treatment with neuroleptic (antipsychotic) drugs was first outlined in the mid-1960s but the effects of such syndromes have been neglected since then. We have pursued evidence for the existence and nature of discontinuation syndromes following neuroleptics through reports of difficulties following the use of dopamine blocking anti-emetics, the use of chlorpromazine to treat tuberculosis, the use of antidepressant-neuroleptic combinations in affective disorders, the occurrence of tardive syndromes and studies designed to establish the existence of discontinuation syndromes in schizophrenia. Combined these bodies of data point strongly to the existence of discontinuation syndromes after cessation of treatment with neuroleptics which may involve features other than motor dyskinesias. There is at present little evidence on the relative frequency of such syndromes or predisposing factors. The area needs research input to establish the nature of the syndromes that may result, their frequency, predisposing factors and best methods of treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434 · see citing works
Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392 · see citing works
Serotonin Reuptake Inhibitor Withdrawal
Coupland, N. J., Bell, C. J., & Potokar, J. P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199610000-00003 · Cited by 303 · see citing works
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301 · see citing works
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246 · cited 3× · see citing works
“Viguera et al. (1997) point to experimental data that support the possibility that withdrawal syndromes may last up to 6 months and the natural history of tardive dyskinesia would support this.”
BackgroundInfluentialNeuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 194 · see citing works
Jeste, D. V., & Caligiuri, M. P. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.2.303 · Cited by 191 · see citing works
Recurrence of Mania after Lithium Withdrawal
Goodwin, G. M. (1994) · The British Journal of Psychiatry · doi:10.1192/bjp.164.2.149 · Cited by 163 · see citing works
Propranolol and polythiazide in treatment of hypertension.
O’Brien, E., & Mackinnon, J. (1972) · Heart · doi:10.1136/hrt.34.10.1042 · Cited by 69 · see citing works
Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine
Meltzer, H. Y., Lee, M. A., Ranjan, R., Mason, E. A., & Cola, P. A. (1996) · Psychopharmacology · doi:10.1007/bf02245619 · Cited by 68 · see citing works
The Epidemiology of Drug-induced Akathisia: Part II. Chronic, Tardive, and Withdrawal Akathisias
Sachdev, P. S. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.3.451 · Cited by 68 · see citing works
Antidepressant withdrawal symptoms treated with anticholinergic agents
Dilsaver, S. C., Feinberg, M. P., & Greden, J. F. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.2.249 · Cited by 67 · see citing works
Greenberg, L. M., & Roth, S. D. (1966) · American Journal of Psychiatry · doi:10.1176/ajp.123.2.221 · Cited by 59 · see citing works
An anti-tardive-dyskinesia effect of verapamil
Barrow, N., & Childs, A. L. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.11.1485a · Cited by 51 · see citing works
Withdrawal effects of phenothiazines
Simpson, G. M., Amin, M., & Kunz, E. (1965) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(65)80028-1 · Cited by 50 · see citing works
Neuroleptic-induced respiratory dyskinesia
Kruk, J., Sachdev, P. S., & Singh, S. (1995) · Journal of Neuropsychiatry · doi:10.1176/jnp.7.2.223 · Cited by 47 · see citing works
Gallant, D. M., EDWARDS, C. G., BISHOP, M. P., et al. (1964) · American Journal of Psychiatry · doi:10.1176/ajp.121.5.491 · Cited by 40 · see citing works
Risks of Withdrawing Antipsychotic Medications
Wyatt, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150037007 · Cited by 38 · see citing works
Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena
Dilsaver, S. C. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90097-z · Cited by 36 · see citing works
Conversions From Clozapine to Other Antipsychotic Drugs
Gardner, D. M. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240089014 · Cited by 31 · see citing works
Serum prolactin levels and their relationship to survival in women with operable breast cancer
Wang, D. Y., Stepniewska, K., Allen, D. S., et al. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00201-z · Cited by 31 · see citing works
Chlorpromazine in nonpsychotic patients with pulmonary tuberculosis.
Hollister, L. E., EIKENBERRY, D. T., & Raffel, S. (1960) · PubMed · doi:10.1164/arrd.1960.81.4.562 · Cited by 29 · see citing works
Clozapine Withdrawal: Serotonergic or Dopaminergic Mechanisms?
Meltzer, H. Y. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200094013 · Cited by 26 · see citing works
Parkinsonism and Tardive Dyskinesia Associated with Long-Term Metoclopramide Therapy
Grimes, J. D. (1981) · New England Journal of Medicine · doi:10.1056/nejm198112033052316 · Cited by 22 · see citing works
Tardive akathisia and agitated depression during metoclopramide therapy
Shearer, R. M., Bownes, I. T., & Curran, P. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb01230.x · Cited by 20 · see citing works
Drug dependence as a criterion for differentiation of psychotropic drugs
Battegay, R. (1966) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(66)80030-5 · Cited by 20 · see citing works
Neuroleptic Withdrawal in Schizophrenic Patients
Meltzer, H. Y. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150032005 · Cited by 18 · see citing works
Why Neuroleptic Withdrawal in Schizophrenia?
Carpenter, W. T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150024003 · Cited by 17 · see citing works
Long-term Treatment for Lifetime Disorders?
Greden, J. F. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150029004 · Cited by 15 · see citing works
The Early Course of Schizophrenia and Long-term Maintenance Neuroleptic Therapy
Nuechterlein, K. H. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150035006 · Cited by 15 · see citing works
Breast cancer in hospitalized psychiatric patients
Goode, D. J., Corbett, W. T., Schey, H. M., et al. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.6.804 · Cited by 14 · see citing works
Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels
Antkiewicz‐Michaluk, L., Karolewicz, B., Michaluk, J., & Vetulani, J. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00571-4 · Cited by 13 · see citing works
Withdrawal effects of metoclopramide.
Noll, A. M., & Pinsky, D. J. (1991) · PubMed · Cited by 5 · see citing works
Long-term neurologic complications of metoclopramide.
Patel, M., & Louis, S. (1986) · PubMed · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · see citing works
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · see citing works
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works
Why is it so difficult to stop psychiatric drug treatment?
Moncrieff, J. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.03.009 · Cited by 59 · see citing works
Experiencing antipsychotic discontinuation: results from a survey of <scp>A</scp>ustralian consumers
Salomon, C., Hamilton, B., & Elsom, S. (2014) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12178 · Cited by 25 · see citing works
- Authors
- Tranter, R., & Healy, D.
- Affiliations
- North Wales Department of Psychological Medicine, Hergest Unit, Bangor LL57 2PW, UK
- ORCID
- Healy, David
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1998-07
- Volume
- 12
- Issue
- 4
- Pages
- 401-406
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2069460670
- Cited by
- 54
- References
- 34
- Citations by year
- 2025: 1 · 2023: 1 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 3 · 2013: 2 · 2012: 1
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- antipsychotic drugs, chlorpromazine, tardive dyskinesia, tuberculosis treatment, mood disorders, schizophrenia, treatment withdrawal
- MeSH terms
- Antiemetics, Chlorpromazine, Dyskinesia, Drug-Induced, Humans, Psychotic Disorders, Substance Withdrawal Syndrome, Antipsychotic Agents, Mood Disorders, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review